<DOC>
	<DOC>NCT02352493</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-CC5 in healthy adult volunteers and subjects with PNH</brief_summary>
	<brief_title>A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH</brief_title>
	<detailed_description />
	<mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
	<mesh_term>Hemoglobinuria</mesh_term>
	<criteria>Adequate complete blood counts, liver and renal function 12lead electrocardiogram (ECG) within normal limits Female subjects of child bearing potential agreeing to use a protocol specified method of contraception Male subjects agreeing to use protocol specified methods of contraception Willing to provide written informed consent and willing to comply with study requirements Any uncontrolled or serious disease, or any medical or surgical condition, that may interfere with participation in the clinical study and/or put the subject at significant risk Received an investigational agent within 90 days before the first dose of study drug or are in followup of another clinical study History of multiple drug allergies or intolerance to subcutaneous injection Parts A and B of the study: Used prescription medications within 14 days or 7 halflives of administration of the first dose of study drug. History of meningococcal infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>PNH</keyword>
	<keyword>RNAi therapeutic</keyword>
</DOC>